The Newsroom

Investigations  /  09.23.2020

Investigation of Fluidgim Corporation

You Have Legal Options

Fluidigm Corporation (FLDM) Accused of Misrepresenting its Business, Operations, and Prospects

During the relevant period, Fluidigm touted its positive financial results.  However, defendants failed to disclose that it was experiencing longer sales cycles and as a result, its revenue was reasonably likely to decline.  The truth was partially revealed on August 1, 2019, when Fluidigm reported second quarter 2019 revenue below analysts’ expectations, citing weakness in its microfluids segment.  On this news, Fluidigm’s share price fell 35%, to close at $8.05 per share on August 2, 2019.  Then, on November 5, 2019, Fluidigm reported that third quarter 2019 revenue had declined 8.5% year-over-year due to mass cytometry instrument sales, which had decreased 23 percent from the prior year.  On this news, Fluidigm’s share price fell 51%, to close at $2.51 per share on November 6, 2019.

If you purchased Fluidigm Corporation (FLDM) securities between February 7, 2019 and November 5, 2019, you have until November 20, 2020, to ask the court to appoint you lead plaintiff for the class.

  • If you would like more information about your rights and potential remedies please send us a message. 

  • Please Note: Neither the submission to nor the receipt of information by Robbins LLP or one of its attorneys through this website constitutes an agreement by our firm to represent the individual and does not create an attorney-client relationship. Please do not send confidential or sensitive information through this website. This information should be communicated through a direct contact with an individual at the firm.

How can we help you?

CONTACT US TODAY | 1 800 350 6003 or [email protected]

Tell us your concerns